AZD0780 (laroprovstat): how it works, status and trials
Phase 3 (AZURE-Outcomes)PillLowering LDL cholesterol
AZD0780 (laroprovstat) is an investigational daily pill that binds PCSK9 and prevents it from destroying LDL receptors. It is in a phase 3 outcome trial and is not approved.
In technical terms: Binds PCSK9 and prevents PCSK9-mediated LDL-receptor degradation.
The highlighted badge marks where AZD0780 (laroprovstat) acts. Open the full map or compare every therapy.
At a glance
- Acts on
- PCSK9 protein
- How it is given
- Oral small molecule · daily
- What the main trial found
- LDL-C −50.7% at 30 mg (phase 2b PURSUIT)
- Status (curated October 25, 2026)
- Phase 3 (AZURE-Outcomes)
Where it fits in the body
The LDL-receptor cycle
LDL particles are cleared from blood when they bind LDL receptors on liver cells. After the particle is taken in, a receptor normally returns to the surface and can be reused many times. PCSK9 escorts the receptor to the lysosome, where it is destroyed. Every PCSK9-pathway drug (5–10) works by keeping more receptors on the surface.
Trials and registry status
From ClinicalTrials.gov, PubMed and openFDA, refreshed monthly. Last run October 27, 2026.
AZD0780 from AstraZeneca
Stage: Phase 3. 6 active of 21 registered trials. 1 new papers in the last 31 days.
- AZURE-Outcomes (NCT07000357): recruiting, primary completion 2029-10-26
Evidence
- PURSUIT (PubMed 40167413)
Common questions
How does AZD0780 (laroprovstat) work?
AZD0780 (laroprovstat) is an investigational daily pill that binds PCSK9 and prevents it from destroying LDL receptors. It is in a phase 3 outcome trial and is not approved. In technical terms: Binds PCSK9 and prevents PCSK9-mediated LDL-receptor degradation. It acts on PCSK9 protein.
How much does AZD0780 (laroprovstat) lower cholesterol or other lipids?
LDL-C −50.7% at 30 mg (phase 2b PURSUIT). Individual results differ, and a clinician can say what to expect for one person.
Is AZD0780 (laroprovstat) approved, and what is the status?
Phase 3 (AZURE-Outcomes) (curated October 25, 2026). Registry stage as of October 27, 2026: AZD0780, Phase 3.
How is AZD0780 (laroprovstat) taken?
Oral small molecule · daily.
Read more
Related therapies
- Statins: Approved (generic)
- Bempedoic acid (Nexletol, Nexlizet): Approved 2020
- Ezetimibe (Zetia): Approved (generic)
- Bile acid sequestrants (colesevelam): Approved (generic)
Educational, not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed October 27, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. Preval Health does not practice medicine; licensed clinicians in a partner network provide care. If you have chest pain or signs of a stroke, call 911.